Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives

May 13, 2025 2:17 PM ETCellectar Biosciences, Inc. (CLRB) StockAI-Generated Earnings Calls Insights6 Comments
(8min)

Earnings Call Insights: Cellectar Biosciences Inc. (CLRB) Q1 2025

Management View

  • Jim Caruso, President and CEO, highlighted the company's continued focus on the PDC platform, radio conjugate pipeline, and regulatory milestones for iopofosine I 131 in Waldenstrom's Macroglobulinemia (WM), noting, "We rapidly scheduled and completed a productive
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Recommended For You

About CLRB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
CLRB--
Cellectar Biosciences, Inc.